Caprock Group LLC Makes New Investment in McKesson Corporation $MCK

Caprock Group LLC purchased a new position in shares of McKesson Corporation (NYSE:MCK) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 7,811 shares of the company’s stock, valued at approximately $6,034,000.

Several other hedge funds have also recently modified their holdings of the stock. Solstein Capital LLC boosted its stake in McKesson by 171.4% in the 2nd quarter. Solstein Capital LLC now owns 38 shares of the company’s stock worth $28,000 after purchasing an additional 24 shares in the last quarter. State of Wyoming acquired a new position in McKesson during the 2nd quarter valued at approximately $29,000. Hopwood Financial Services Inc. purchased a new position in shares of McKesson in the third quarter worth $31,000. Delos Wealth Advisors LLC acquired a new stake in shares of McKesson during the second quarter worth $35,000. Finally, Abound Wealth Management lifted its stake in shares of McKesson by 104.3% during the third quarter. Abound Wealth Management now owns 47 shares of the company’s stock worth $37,000 after buying an additional 24 shares during the period. Institutional investors and hedge funds own 85.07% of the company’s stock.

McKesson Stock Performance

NYSE MCK opened at $934.41 on Wednesday. The firm has a market capitalization of $114.46 billion, a P/E ratio of 26.87, a PEG ratio of 1.55 and a beta of 0.40. The stock has a 50-day simple moving average of $832.63 and a two-hundred day simple moving average of $783.87. McKesson Corporation has a fifty-two week low of $585.22 and a fifty-two week high of $971.93.

McKesson (NYSE:MCK) last posted its earnings results on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, topping the consensus estimate of $9.19 by $0.15. The firm had revenue of $106.16 billion for the quarter, compared to analyst estimates of $105.98 billion. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.McKesson’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period last year, the company earned $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, analysts forecast that McKesson Corporation will post 32.77 earnings per share for the current year.

McKesson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Stockholders of record on Monday, March 2nd will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, March 2nd. McKesson’s payout ratio is 9.43%.

Insider Activity at McKesson

In related news, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the firm’s stock in a transaction on Friday, February 6th. The shares were sold at an average price of $955.00, for a total transaction of $313,240.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Thomas L. Rodgers sold 276 shares of McKesson stock in a transaction on Monday, January 5th. The shares were sold at an average price of $816.18, for a total transaction of $225,265.68. Following the completion of the transaction, the executive vice president directly owned 2,268 shares of the company’s stock, valued at $1,851,096.24. The trade was a 10.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.08% of the stock is owned by insiders.

More McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: JPMorgan upgraded MCK to “Overweight” and raised its price target from $983 to $1,107, implying notable upside vs. recent levels — this is a clear bullish catalyst for investor demand. Benzinga
• Positive Sentiment: High-profile media/TV support (Jim Cramer praising McKesson) can boost retail interest and short-term buying flows. Cramer piece
• Positive Sentiment: Recent earnings beat and FY26 EPS guidance (38.80–39.20) plus a new quarterly dividend ($0.82/share) support the fundamental bull case for long-term investors. MarketBeat summary
• Neutral Sentiment: McKesson is attracting investor attention on screens (Zacks notes it’s among most-watched stocks), which can increase volatility but doesn’t itself imply direction. Zacks
• Neutral Sentiment: Coverage on automation and robotics (could improve logistics/efficiency long term) highlights an operational upside but is speculative for near-term earnings. Pharma-Technology
• Negative Sentiment: Insider selling: CAO Napoleon Rutledge Jr. sold 328 shares (filed with SEC) — small in size relative to the company but often interpreted negatively by some investors. InsiderTrades
• Negative Sentiment: McKesson reported flat revenues in its Medical‑Surgical segment, which may concern investors focused on near-term organic growth and margin leverage. HME News

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Mizuho upped their target price on McKesson from $880.00 to $885.00 and gave the company a “neutral” rating in a research report on Thursday, February 5th. TD Cowen boosted their price target on McKesson from $1,000.00 to $1,012.00 and gave the company a “buy” rating in a research note on Thursday, February 5th. JPMorgan Chase & Co. increased their price objective on McKesson from $983.00 to $1,107.00 and gave the company an “overweight” rating in a report on Tuesday. Robert W. Baird set a $968.00 price objective on McKesson in a research note on Wednesday, January 14th. Finally, Zacks Research downgraded McKesson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 25th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $937.07.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.